BioScience Trends
Online ISSN : 1881-7823
Print ISSN : 1881-7815
ISSN-L : 1881-7815
Current issue
Displaying 1-10 of 10 articles from this issue
Review
  • Ya-nan Ma, Kenji Karako, Peipei Song, Xiqi Hu, Ying Xia
    2025 Volume 19 Issue 3 Pages 243-251
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 17, 2025
    JOURNAL FREE ACCESS

    Stroke remains a leading cause of mortality and long-term disability worldwide, frequently resulting in impairments in motor control, cognition, and emotional regulation. Conventional rehabilitation approaches, while partially effective, often lack individualization and yield suboptimal outcomes. In recent years, brain-computer interface (BCI) technology has emerged as a promising neurorehabilitation tool by decoding neural signals and providing real-time feedback to enhance neuroplasticity. This review systematically explores the use of BCI systems in post-stroke rehabilitation, focusing on three core domains: motor function, cognitive capacity, and emotional regulation. This review outlines the neurophysiological principles underpinning BCI-based motor rehabilitation, including neurofeedback training, Hebbian plasticity, and multimodal feedback strategies. It then examines recent advances in upper limb and gait recovery using BCI integrated with functional electrical stimulation (FES), robotics, and virtual reality (VR). Moreover, it highlights BCI's potential in cognitive and language rehabilitation through EEG-based neurofeedback and the integration of artificial intelligence (AI) and immersive VR environments. In addition, it discusses the role of BCI in monitoring and regulating post-stroke emotional disorders via closed-loop systems. While promising, BCI technologies face challenges related to signal accuracy, device portability, and clinical validation. Future research should prioritize multimodal integration, AI-driven personalization, and large-scale randomized trials to establish long-term efficacy. This review underscores BCI's transformative potential in delivering intelligent, personalized, and cross-domain rehabilitation solutions for stroke survivors.

    Download PDF (734K)
  • Mingyu Liu, Wenli Zhang, Junyu Wang, Kehan Bao, Ziyi Fu, Boyuan Wang
    2025 Volume 19 Issue 3 Pages 252-265
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 29, 2025
    JOURNAL FREE ACCESS

    In the context of the rising global prevalence of obesity, traditional intervention measures have proven insufficient to meet the demands of personalized and sustainable health management, necessitating the exploration of innovative solutions through innovative technologies. This study explores how advanced digital technologies, including Internet of Things (IoT) and Artificial Intelligence (AI), can manage weight and enhance full-lifecycle health in individuals with obesity under simulated high-altitude hypoxic conditions (HC). The findings suggest that integrating simulated HC with digital health technologies offers a novel and safe approach to obesity rehabilitation. By leveraging environmental stimuli, real-time monitoring through wearable devices, and intelligent evaluation using large language models (LLMs), this method enables more scientific weight loss, prevents rebound weight gain, and fosters proactive healthy lifestyles, significantly improving weight control outcomes for individuals with obesity. Future research should evaluate the efficacy of simulated HC in weight management and its long-term impact on obesity control. Establishing an integrated framework that combines simulated HC, lifestyle interventions, and smart health ecosystems is crucial for advancing rehabilitative healthcare and addressing the global burden of obesity through digital innovation.

    Download PDF (3112K)
  • Zhi-Quan Xu, Shi-Qiao Luo, Zhong-Jun Wu, Rui Liao
    2025 Volume 19 Issue 3 Pages 266-280
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 22, 2025
    JOURNAL FREE ACCESS

    Hepatocellular carcinoma (HCC) risk factors and incidence vary globally, but men generally have higher incidence than women. Men also tend to have a worse prognosis in terms of survival period and pathological characteristics. Furthermore, there are notable gender differences in treatment strategies and drug responses. While traditional risk factors such as hepatitis B virus, hepatitis C virus, alcohol consumption, and metabolic syndrome contribute to these differences, the underlying molecular mechanisms remain partly understood. Recent research has focused on elucidating the roles of sex hormones, DNA damage and repair pathways, immune microenvironments, and genetic/epigenetic factors in driving gender-specific disparities. For instance, estrogen receptor signaling has been shown to suppress HCC progression, whereas androgen receptor signaling promotes tumor development. Additionally, immune cells such as tumor-associated macrophages and regulatory T cells exhibit gender-specific patterns, with males typically showing higher levels of immunosuppressive cells. Omics analyses, including genomics, transcriptomics, and proteomics, have further revealed sex-specific differences in gene expression, protein interactions, and metabolic pathways. Despite these advances, significant gaps remain in understanding the interplay between environmental, hormonal, and genetic factors in shaping gender disparities in HCC. Future research should prioritize the identification of novel molecular targets, the development of gender-specific therapeutic strategies, and the integration of multi-omics data to address these disparities. Addressing these challenges will be critical for improving diagnostic, prognostic, and therapeutic outcomes in HCC patients of both sexes.

    Download PDF (1716K)
  • Yuqi Wang, Fanghua Qi, Min Li, Yuan Xu, Li Dong, Pingping Cai
    2025 Volume 19 Issue 3 Pages 281-295
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: June 15, 2025
    JOURNAL FREE ACCESS

    Obesity has emerged as a global health crisis, imposing substantial burdens on both individual well-being and socioeconomic development. The pathogenesis of obesity primarily stems from disrupted energy homeostasis, wherein the hypothalamus plays a pivotal role through its complex neuropeptide networks that regulate appetite and energy balance. Recent advances have highlighted the therapeutic potential of traditional Chinese medicine (TCM) in modulating hypothalamic appetite regulation. This comprehensive review systematically evaluates current evidence from PubMed and China National Knowledge Infrastructure databases, focusing on the mechanisms by which TCM interventions influence hypothalamic neuropeptide signaling pathways. Our analysis reveals that various TCM modalities, including bioactive compounds (e.g., berberine and, evodiamine), herbal formulations (e.g., Pingwei Powder, Fangji Huangqi Decoction), plant extracts (e.g., Cyclocarya paliurus aqueous extract), and Chinese patent medicines (e.g., Danzhi Jiangtang Capsules and Jingui Shenqi Pills), have significant effects on key appetite-regulating pathways. These effects are mediated through modulation of critical neuropeptide systems, particularly AgRP/NPY and POMC/CART neurons, as well as leptin signaling. These findings not only provide mechanistic insights into TCM's anti-obesity effects but also demonstrate the value of integrating traditional medicine with modern pharmacological approaches. The synergistic potential of TCM formulas, when combined with contemporary research methodologies, offers promising avenues for developing novel therapeutic strategies for obesity and related metabolic disorders.

    Download PDF (1442K)
  • Xiangyi Tang, Cheng Wang, Xiling Zhang, Qibin Liao, Hongzhou Lu
    2025 Volume 19 Issue 3 Pages 296-308
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 29, 2025
    JOURNAL FREE ACCESS

    Acquired immunodeficiency syndrome (AIDS)/human immunodeficiency virus (HIV) patients experience significant increase in their survival and decline in the mortality with the advent of antiretroviral therapy (ART). Nonetheless, ART alone still cannot completely cure AIDS/HIV patients. Furthermore, the virus remains latent in resting CD4+T cells for extended periods, posing a continuous threat to AIDS/HIV patients. Immune checkpoint blockades (ICBs), as a promising immunotherapy, inaugurate new pathways for AIDS/HIV cure or remission given their capability to break down the latency limit of HIV, and promote the regeneration and activation of HIV-specific T cells. However, not all AIDS/HIV patients respond to immune checkpoint inhibitors (ICIs), similar to that encountered in cancer patients, accompanied by the risk of severe immune-related adverse events (irAEs) in some cases. Accordingly, the present study was conducted to explore the possibility of personalized medicine tailored to the host discrepancy, with purposes of achieving better treatment outcomes, higher objective response rates, and fewer irAEs. Strategies for ICIs based on individual differences are documented to be conducive to improving therapeutic outcomes for patients. Therefore, this study intended to improving the therapeutic efficacy of ICIs in AIDS/HIV patients within the context of precision immunotherapy, including monotherapy and combination strategies, as well as the application of predictive biomarkers.

    Download PDF (1215K)
  • Caterina Accardo, Ivan Vella, Fabrizio di Francesco, Sergio Rizzo, Ser ...
    Article type: review-article
    2025 Volume 19 Issue 3 Pages 309-327
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: March 18, 2025
    JOURNAL FREE ACCESS

    Despite the continued high prevalence of colorectal cancer in the Western world, recent years have witnessed a decline in its mortality rate, largely attributable to the sustained advancement of multimodal treatment modalities for metastatic patients. One persisting issue is lack of consensus between different centres and multidisciplinary teams regarding definition of resectability, the duration of chemotherapy treatment, and surgical strategy. This narrative review outlines current multimodal treatment of patients with colon cancer metastatic to the liver and/or lung in different clinical scenarios. Currently, there are multiple multimodal strategies that can be employed to enhance resectability in these patients. These include novel and sophisticated target therapies (such as novel immunotherapeutic modalities and micro RNAs), complex resections utilising parenchyma-sparing techniques, liver transplantation, and cytoreductive strategies in patients for whom a curative option is not feasible. It is the responsibility of the scientific community to establish standardised protocols across different centres, based on the most recent evidence, while maintaining a high degree of personalisation of treatment for each individual patient. It seems likely that artificial intelligence (AI) will play a significant role in achieving this goal.

    Download PDF (689K)
Original Article
  • Kosuke Hatta, Ryota Tanaka, Kenjiro Kimura, Naoki Yamashita, Jie Li, T ...
    2025 Volume 19 Issue 3 Pages 328-336
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: June 14, 2025
    JOURNAL FREE ACCESS

    Indocyanine green (ICG)-C9, a novel cyanine dye developed by the Center for Biosystems Dynamics Research at RIKEN, provides significant advantages over conventional ICG due to its detectability via shortwave-infrared (SWIR) fluorescence imaging. Unlike standard ICG, ICG-C9 facilitates SWIR imaging and displays therapeutic potential when conjugated with antibodies in vivo, suggesting broader applicability across various cancer types. This study evaluated the efficacy of SWIR fluorescence imaging with ICG-C9 in comparison with existing near-infrared (NIR) imaging techniques. We assessed excretion kinetics and the relationship between excitation and fluorescence wavelengths for ICG-C9 and ICG following intravenous administration in BALB/c-nu mice. Tumor uptake was evaluated using a cell-line-derived subcutaneous tumor model from HuH-7 cells, representing hepatocellular carcinoma. Variables including dose, administration route, and exposure time were optimized for comparison. Maximum fluorescence intensity for ICG-C9 was observed with an excitation wavelength of 915 nm and fluorescence emission wavelengths >950 nm within the SWIR spectrum. Both ICG-C9 and ICG followed similar excretion pathways, involving hepatic uptake and biliary excretion. Tumor uptake of ICG-C9 was confirmed under similar conditions to ICG. ICG-C9 demonstrates promising potential as an alternative to NIR fluorescence imaging with ICG, offering unique properties that may enhance imaging capabilities. However, further research is required to establish its clinical applicability and broader therapeutic utility.

    Download PDF (1210K)
  • Jiejun Hu, Junhua Gong, Xia Shu, Xin Dai, Dong Cai, Zhibo Zhao, Jinhao ...
    2025 Volume 19 Issue 3 Pages 337-350
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 15, 2025
    JOURNAL FREE ACCESS

    The pre-mRNAs splicing is important mechanisms of hepatocellular carcinoma (HCC) progression. Hence, this study aimed to explore the function and corresponding mechanisms of small nuclear ribonucleoprotein polypeptide A (SNRPA), a vital RNAs splicing molecule, in HCC. Here, the University of Alabama at Birmingham CANcer data analysis portal (UALCAN), western blotting, and immunohistochemistry indicated that SNRPA levels were elevated in HCC tissues. Moreover, high expression of SNRPA was correlated with unfavorable clinicopathologic features and poor survival in HCC patients. A series of in vitro and in vivo gain/loss-of-function experiments reported that SNRPA promoted the proliferation of HCC cells. Integrated nanopore full-length cDNA sequencing and RNA-binding protein immunoprecipitation sequencing revealed that B7 homologue 6 (B7-H6) was a potential target of SNRPA. Subsequently, western blotting and flow cytometry showed that SNRPA activated B7-H6-STAT3/AKT signaling axis in HCC cells with promotion of G1-S transition in the cell cycle and inhibition of cell apoptosis. Mechanistically, RNA-binding protein immunoprecipitation and polymerase chain reaction with using exon-exon and exon-intron junction primers revealed that SNRPA facilitated B7-H6 pre-mRNA maturation by binding to it directly and contributing to its intron 2 splicing. Moreover, drug sensitivity test found that SNRPA induced HCC cell resistance to lenvatinib. Finally, restoration experiments demonstrated that the effects of SNRPA on HCC cells relied on B7- H6 expression. Taken together, SNRPA promotes HCC growth and lenvatinib resistance via B7-H6-STAT3/AKT axis through facilitating B7-H6 pre-mRNA maturation by maintaining its intron 2 splicing. Thus, SNRPA may be a promising target for HCC therapy and lenvatinib resistance reversion.

    Download PDF (12929K)
  • Xuedong Wang, Pengfei Wang, Bingjun Tang, Jiahao Xu, Baidong Wang, Lih ...
    2025 Volume 19 Issue 3 Pages 351-360
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 22, 2025
    JOURNAL FREE ACCESS

    The prognostic significance of preoperative platelet counts among patients with hepatocellular carcinoma (HCC) undergoing curative resection remains controversial. The objective of the current study was to investigate the impact of preoperative platelet count on long-term outcomes after HCC resection. Patients who underwent curative-intent resection for HCC between 2000 and 2021 at 10 hepatobiliary centers in China were retrospectively analyzed. Patients were categorized based on platelet count within 2 weeks before surgery: thrombocytopenia (< 100 × 109/L), normal platelet count (100-299 × 109/L), and thrombocytosis (≥ 300 × 109/L). The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). Among 3,116 patients, 655 (21.0%) had thrombocytopenia, 2,374 (76.2%) had normal platelet counts, and 87 (2.8%) had thrombocytosis. The 5-year OS was 52.7%, 56.0%, and 40.2% for thrombocytopenia, normal platelet count, and thrombocytosis groups, respectively (p < 0.001 among the three groups); the corresponding 5-year RFS was 39.3%, 39.3%, and 26.9%, respectively (p = 0.001 among the three groups). Multivariable analysis identified both thrombocytopenia (HR 1.215, 95% CI 1.045-1.413, p = 0.011) and thrombocytosis (HR 1.307, 95% CI 1.130-1.511, p < 0.001) as independent risk factors for worse OS, and thrombocytosis was independently associated with worse RFS (HR 1.523, 95% CI 1.196-1.939, p = 0.001). Both thrombocytopenia and thrombocytosis were associated with worse survival after HCC resection, with thrombocytosis also predicting higher risk of recurrence. Routine preoperative platelet count may serve as a valuable and practical prognostic marker for risk stratification among patients with HCC undergoing resection.

    Download PDF (815K)
  • Keda Song, Yang Xu, Zhongyu Li, Mingyuan Wang, Dong Chen, Yongzhi Zhou ...
    2025 Volume 19 Issue 3 Pages 361-367
    Published: June 30, 2025
    Released on J-STAGE: July 04, 2025
    Advance online publication: April 09, 2025
    JOURNAL FREE ACCESS

    One of the challenges of laparoscopic liver resection (LLR) is the exposure of the surgical field. We propose a new surgical approach to better expose the right liver, stretching of the ligamentum teres hepatis (SLTH), and we evaluated its clinical feasibility and limitations through a study analyzing relevant cases. Clinicopathologic data on patients who underwent laparoscopic right partial hepatectomy (LRPH) at our center were retrospectively collected, and subjects were 276 patients with liver space-occupying lesions who met the selection criteria and who underwent the new surgical approach (SLTH) or the conventional surgical approach (no stretching of the ligamentum teres hepatis, or NSLTH). After 1:1 propensity score matching (PSM), 102 patients in each cohort were selected for further analysis. There were no significant differences in the operating time or the duration of postoperative hospitalization between the SLTH cohort and the NSLTH cohort. The duration of detachment of the hepatic parenchyma and the duration of hepatic portal occlusion were significantly shorter in the SLTH cohort than in the NSLTH cohort. The intraoperative blood loss in the SLTH cohort was significantly less than that in the NSLTH cohort. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly lower in the SLTH cohort than in the NSLTH cohort on day 5 postoperatively. Results confirmed that SLTH is a simple, safe, effective, and highly reproducible technique for the treatment of LRPH. SLTH may help to perform LRPH by increasing the level of laparoscopic exposure of the right liver and reducing bleeding and operating time.

    Download PDF (516K)
feedback
Top